Sage NMDA Modulator Fails In Alzheimer’s Months After Parkinson’s Disappointment

 
• By Joseph Haas
  
Sage missed on the second of three Phase II studies of dalzanemdor in neurodegenerative disease

More from Clinical Trials

More from R&D